Allspring Global Investments Holdings LLC Purchases 15,431 Shares of argenx SE (NASDAQ:ARGX)

Allspring Global Investments Holdings LLC lifted its position in argenx SE (NASDAQ:ARGX) by 21.8% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 86,187 shares of the company’s stock after purchasing an additional 15,431 shares during the period. Allspring Global Investments Holdings LLC owned about 0.15% of argenx worth $32,788,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. grew its holdings in shares of argenx by 30.4% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 14,470 shares of the company’s stock worth $5,505,000 after purchasing an additional 3,374 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of argenx by 388.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,719 shares of the company’s stock worth $1,415,000 after purchasing an additional 2,958 shares during the last quarter. RTW Investments LP grew its holdings in shares of argenx by 5.2% in the third quarter. RTW Investments LP now owns 507,195 shares of the company’s stock worth $249,352,000 after purchasing an additional 25,000 shares during the last quarter. Townsquare Capital LLC grew its holdings in shares of argenx by 96.6% in the third quarter. Townsquare Capital LLC now owns 3,442 shares of the company’s stock worth $1,692,000 after purchasing an additional 1,691 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of argenx by 41.1% in the third quarter. Northern Trust Corp now owns 39,936 shares of the company’s stock worth $19,634,000 after purchasing an additional 11,627 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on ARGX. Evercore ISI dropped their price target on argenx from $594.00 to $436.00 and set an “outperform” rating for the company in a research note on Thursday, December 21st. JMP Securities reaffirmed a “market outperform” rating and issued a $471.00 price target on shares of argenx in a research note on Friday, March 22nd. Wells Fargo & Company raised their price target on argenx from $472.00 to $478.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 20th. William Blair lowered argenx from an “outperform” rating to a “market perform” rating in a research note on Wednesday, December 20th. Finally, Piper Sandler raised their price target on argenx from $518.00 to $522.00 and gave the stock an “overweight” rating in a research note on Friday, January 26th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and an average price target of $530.74.

argenx Stock Performance

NASDAQ ARGX opened at $378.02 on Friday. argenx SE has a one year low of $327.73 and a one year high of $550.76. The stock has a 50-day moving average of $390.49 and a 200 day moving average of $425.06. The company has a market capitalization of $22.42 billion, a price-to-earnings ratio of -73.54 and a beta of 0.65.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The business had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. During the same quarter in the previous year, the business posted ($0.70) earnings per share. On average, equities analysts predict that argenx SE will post -2 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.